Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608881 · ClinicalTrials.gov registry record · Phase 3
Coenzyme Q10 in Huntington's Disease (HD)
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 609
- Enrollment target
NCT00608881: Clinical Trial Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00608881 is a Phase 3 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 609 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608881, a Phase 3 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 609 participants
- Enrollment target
Study Summary
The goals of this trial are to determine if coenzyme Q10 is effective in slowing the worsening symptoms of Huntington's disease and to learn about the safety and acceptability of long-term coenzyme Q10 use by determining its effects on people with Huntington's disease.
Primary Outcome
The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capac
Interventions
- OTHER placebo
- DRUG coenzyme Q10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2008-03 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Why NCT00608881 stopped before completion
NCT00608881 is an interventional study that assigns participants to a tested intervention. The registered 609 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00608881 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00608881 about?
NCT00608881 is a clinical study titled "Coenzyme Q10 in Huntington's Disease (HD)". The goals of this trial are to determine if coenzyme Q10 is effective in slowing the worsening symptoms of Huntington's disease and to learn about the safety and acceptability of long-term coenzyme Q10 use by determining its effects on people with Huntington's disease.
What is the current status of trial NCT00608881?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2008-03. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00608881?
The interventions under investigation include: placebo (OTHER), coenzyme Q10 (DRUG).
Who is sponsoring clinical trial NCT00608881?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00608881's enrollment target sits among peer trials
609 602nd of 2000 higher than 1,398 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
- NCT05838638 · 610 participants · NA
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
- NCT07075718 · 610 participants · Phase 2
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia